Jeff Yass’s Aclaris Therapeutics ACRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.18M | Buy |
412,549
+32,619
| +9% | +$145K | ﹤0.01% | 6289 |
|
|
2026
Q1 | $1.42M | Sell |
379,930
-536,916
| -59% | -$1.81M | ﹤0.01% | 7018 |
|
|
2025
Q4 | $2.76M | Buy |
916,846
+880,609
| +2,430% | +$2.23M | ﹤0.01% | 5023 |
|
|
2025
Q3 | $68.8K | Sell |
36,237
-84,910
| -70% | -$148K | ﹤0.01% | 11747 |
|
|
2025
Q2 | $172K | Sell |
121,147
-1,260,594
| -91% | -$1.71M | ﹤0.01% | 11363 |
|
|
2025
Q1 | $2.11M | Buy |
1,381,741
+1,302,694
| +1,648% | +$2.78M | ﹤0.01% | 5405 |
|
|
2024
Q4 | $196K | Buy |
79,047
+16,639
| +27% | +$41.4K | ﹤0.01% | 10748 |
|
|
2024
Q3 | $71.8K | Sell |
62,408
-144,192
| -70% | -$177K | ﹤0.01% | 11225 |
|
|
2024
Q2 | $227K | Buy |
206,600
+83,140
| +67% | +$97.7K | ﹤0.01% | 10069 |
|
|
2024
Q1 | $153K | Sell |
123,460
-30,149
| -20% | -$36K | ﹤0.01% | 10886 |
|
|
2023
Q4 | $161K | Buy |
153,609
+29,759
| +24% | +$90.8K | ﹤0.01% | 10901 |
|
|
2023
Q3 | $848K | Buy |
123,850
+103,840
| +519% | +$887K | ﹤0.01% | 7007 |
|
|
2023
Q2 | $208K | Sell |
20,010
-8,466
| -30% | -$76.6K | ﹤0.01% | 10196 |
|
|
2023
Q1 | $230K | Buy |
+28,476
| New | +$361K | ﹤0.01% | 10288 |
|
|
2022
Q4 | – | Sell |
-22,536
| Closed | -$363K | – | 12263 |
|
|
2022
Q3 | $355K | Buy |
+22,536
| New | +$355K | ﹤0.01% | 9365 |
|
|
2022
Q2 | – | Sell |
-29,100
| Closed | -$408K | – | 12770 |
|
|
2022
Q1 | $502K | Buy |
29,100
+5,409
| +23% | +$73.8K | ﹤0.01% | 8955 |
|
|
2021
Q4 | $344K | Buy |
23,691
+10,574
| +81% | +$160K | ﹤0.01% | 10153 |
|
|
2021
Q3 | $236K | Sell |
13,117
-58,347
| -82% | -$935K | ﹤0.01% | 11128 |
|
|
2021
Q2 | $1.25M | Sell |
71,464
-376,171
| -84% | -$8.54M | ﹤0.01% | 7122 |
|
|
2021
Q1 | $11.3M | Buy |
447,635
+337,086
| +305% | +$6.59M | ﹤0.01% | 2595 |
|
|
2020
Q4 | $715K | Buy |
+110,549
| New | +$466K | ﹤0.01% | 7489 |
|
|
2020
Q1 | – | Sell |
-30,642
| Closed | -$58K | – | 10154 |
|
|
2019
Q4 | $58K | Buy |
30,642
+2,157
| +8% | +$3.58K | ﹤0.01% | 9305 |
|
|
2019
Q3 | $31K | Sell |
28,485
-42,408
| -60% | -$60.2K | ﹤0.01% | 9888 |
|
|
2019
Q2 | $155K | Buy |
70,893
+55,923
| +374% | +$305K | ﹤0.01% | 9342 |
|
|
2019
Q1 | $90K | Buy |
+14,970
| New | +$99.2K | ﹤0.01% | 8290 |
|
|
2018
Q3 | – | Sell |
-23,032
| Closed | -$460K | – | 9096 |
|
|
2018
Q2 | $460K | Buy |
23,032
+10,334
| +81% | +$191K | ﹤0.01% | 6957 |
|
|
2018
Q1 | $222K | Sell |
12,698
-60,396
| -83% | -$1.28M | ﹤0.01% | 8157 |
|
|
2017
Q4 | $1.8M | Buy |
+73,094
| New | +$1.78M | ﹤0.01% | 4086 |
|
|
2017
Q2 | – | Sell |
-33,793
| Closed | -$1.01M | – | 9103 |
|
|
2017
Q1 | $1.01M | Buy |
+33,793
| New | +$974K | ﹤0.01% | 5113 |
|
Other funds holding ACRS
RCM
BCM
DTC
VC
FLSM
RSCM
DC
Jeff Yass's ACRS Position: Q2 2026 in Review
Jeff Yass increased its Aclaris Therapeutics (ACRS) stake by 8.6% in Q2 2026, buying an estimated $145K and bringing the position to 412,549 shares worth $2.18M. The position accounts for ﹤0.01% of the portfolio, ranked #6289.
Jeff Yass first reported a position in ACRS in Q1 2017 and has held it in 29 quarters since. The position peaked at $11.3M in Q1 2021. 148 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.
- Jeff Yass held 412,549 shares of Aclaris Therapeutics worth $2.18M as of Q2 2026.
- Jeff Yass bought 32,619 Aclaris Therapeutics shares in Q2 2026, an estimated $145K.
- Aclaris Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #6289 holding.
- Jeff Yass first reported a position in Aclaris Therapeutics in Q1 2017 and has held it in 29 quarters since.
- Jeff Yass's Aclaris Therapeutics position peaked at $11.3M in Q1 2021.
- 148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.